NST NeuroSurvival Technologies Ltd. Release: APOSENSE(R) [18F]-ML-10 for Molecular Imaging of Apoptosis to Proceed to Phase I/II Trials  
7/23/2008 10:44:28 AM

PETCH-TIKVA, ISRAEL--(Marketwire - July 23, 2008) - NST NeuroSurvival Technologies Ltd. (NST), a clinical phase company developing molecular imaging agents and drugs that identify and target cells undergoing apoptosis (programmed cell death), today announced that the U.S. Food and Drug Administration (FDA) issued a "safe to proceed" letter for the company's APOSENSE® [18F]-ML-10 Investigational New Drug Application (IND).